SCHEMBL23324801

SCHEMBL23324801

CC(C)c1nccc2c1-n1c(=O)nc(N3CCNC[C@@H]3C)c3cc(F)c(nc31)-c1c(F)cccc1OCCCC2

nearest known ligand 0.75

Predicted protein targets (top 2)

geneUniProtsupporting neighboursconfidence
KRAS P01116 20/20 0.75
SOS1 Q07889 1/20 0.51

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL23685382 0.99 KRAS (0.75) KRASSOS1
SCHEMBL24660321 0.92 KRAS (0.67) KRASSOS1
SCHEMBL23308440 0.92 KRAS (0.65) KRASSOS1
SCHEMBL25887398 0.89 KRAS (0.79) KRASSOS1
SCHEMBL22848335 0.88 KRAS (0.60) KRASSOS1
SCHEMBL23308441 0.88 KRAS (0.60) KRASSOS1
SCHEMBL23308453 0.88 KRAS (0.60) KRASSOS1
SCHEMBL24660281 0.87 KRAS (0.59) KRASSOS1
SCHEMBL24574302 0.87 KRAS (0.60) KRASSOS1
SCHEMBL23308452 0.87 KRAS (0.57) KRASSOS1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11697657-B2 Small molecule inhibitors of KRAS G12C mutant MERCK SHARP & DOHME LLC (US) 2023-07-11 US disclosed
WO-2021086833-A1 SMALL MOLECULE INHIBITORS OF KRAS G12C MUTANT MERCK SHARP & DOHME CORP. (US) 2021-05-06 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11697657-B2 Small molecule inhibitors of KRAS G12C mutant KRAS, NRAS, HRAS KRAS 1/4885SOS1 320/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.